Traders Sell Shares of Eli Lilly and Co. (LLY) on Strength on Insider Selling
Investors sold shares of Eli Lilly and Co. (NYSE:LLY) on strength during trading on Monday following insider selling activity. $66.06 million flowed into the stock on the tick-up and $110.85 million flowed out of the stock on the tick-down, for a money net flow of $44.79 million out of the stock. Of all companies tracked, Eli Lilly and had the 0th highest net out-flow for the day. Eli Lilly and traded up $0.97 for the day and closed at $83.06Specifically, insider Maria A. Crowe sold 2,248 shares of the company’s stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the transaction, the insider now owns 94,319 shares in the company, valued at $7,674,737.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Donald A. Zakrowski sold 1,213 shares of the company’s stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $83.16, for a total transaction of $100,873.08. Following the transaction, the insider now owns 1,300 shares of the company’s stock, valued at approximately $108,108. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
Several equities analysts have recently commented on LLY shares. Citigroup Inc. restated a “buy” rating on shares of Eli Lilly and in a research report on Wednesday, August 3rd. Argus upped their price objective on shares of Eli Lilly and from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, August 2nd. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price objective for the company in a report on Friday, July 29th. BMO Capital Markets reaffirmed a “buy” rating and issued a $94.00 price objective on shares of Eli Lilly and in a report on Wednesday, July 27th. Finally, Jefferies Group upped their price objective on shares of Eli Lilly and from $100.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, July 14th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Buy” and a consensus target price of $97.06.
The company’s 50-day moving average is $79.63 and its 200 day moving average is $77.69. The company has a market cap of $86.53 billion, a P/E ratio of 35.26 and a beta of 0.17.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.86. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The firm had revenue of $5.40 billion for the quarter, compared to analysts’ expectations of $5.14 billion. During the same quarter last year, the business earned $0.90 earnings per share. The company’s revenue was up 8.6% compared to the same quarter last year. Analysts forecast that Eli Lilly and Co. will post $3.59 EPS for the current year.
A number of institutional investors have recently modified their holdings of the company. Eaton Vance Management boosted its position in shares of Eli Lilly and by 72.3% in the second quarter. Eaton Vance Management now owns 5,498,527 shares of the company’s stock worth $433,009,000 after buying an additional 2,307,920 shares during the period. Renaissance Technologies LLC boosted its position in shares of Eli Lilly and by 565.1% in the first quarter. Renaissance Technologies LLC now owns 2,213,605 shares of the company’s stock worth $159,402,000 after buying an additional 1,880,800 shares during the period. Beutel Goodman & Co Ltd. bought a new position in shares of Eli Lilly and during the second quarter worth about $104,345,000. Janus Capital Management LLC boosted its position in shares of Eli Lilly and by 15.9% in the second quarter. Janus Capital Management LLC now owns 10,021,381 shares of the company’s stock worth $789,162,000 after buying an additional 1,377,814 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Eli Lilly and by 2.2% in the second quarter. Vanguard Group Inc. now owns 63,236,677 shares of the company’s stock worth $4,979,889,000 after buying an additional 1,350,329 shares during the period. Hedge funds and other institutional investors own 74.96% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.